Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Hereditary Sensory and Autonomic Neuropathies 3Endometrial Neoplasms 3Neoplasms 2Breast Neoplasms 2Neoplasm Metastasis 1Lung Neoplasms 1Head and Neck Neoplasms 1Genital Diseases 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Endometrioid 1Advanced Solid Tumor 1Advanced Nonhematologic Malignancies 1

Interventions

Injections 24pembrolizumab 13toripalimab 12tislelizumab 9Gemcitabine 7Cisplatin 7Carboplatin 6atezolizumab 5Nivolumab 5Irinotecan 5Pemetrexed 4Oxaliplatin 4Leucovorin 4Fluorouracil 4Docetaxel 4Cetuximab 4trastuzumab deruxtecan 3spartalizumab 3cediranib 3Paclitaxel 3PM 01183 3Capecitabine 3sintilimab 2olaparib 2lenvatinib 2glumetinib 2camrelizumab 2apatinib 2Therapeutics 2Midazolam 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Solid Tumor × serabelisib × Clear all
NCT05300048 2026-04-30

Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations

Faeth Therapeutics

Phase 1 Terminated
34 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡